Merck Manual

Please confirm that you are a health care professional

honeypot link

Vancomycin

By

Brian J. Werth

, PharmD, University of Washington School of Pharmacy

Last full review/revision May 2020
Click here for Patient Education

Pharmacokinetics

Vancomycin is not appreciably absorbed from a normal gastrointestinal tract after oral administration. Given parenterally, it penetrates into bile and pleural, pericardial, synovial, and ascitic fluids. However, penetration into even inflamed cerebrospinal fluid is low and erratic.

Vancomycin is excreted unchanged by glomerular filtration.

Indications for Vancomycin

Vancomycin is active against

However, many strains of enterococci and some strains of S. aureus are resistant.

However, vancomycin is less effective than antistaphylococcal beta-lactams for methicillin-susceptible S. aureus infections. Vancomycin is used with other antibiotics when treating methicillin-resistant coagulase-negative staphylococcal prosthetic valve endocarditis or enterococcal endocarditis. Vancomycin has also been used as an alternative drug for pneumococcal meningitis Acute Bacterial Meningitis Acute bacterial meningitis is rapidly progressive bacterial infection of the meninges and subarachnoid space. Findings typically include headache, fever, and nuchal rigidity. Diagnosis is by... read more caused by strains with reduced penicillin sensitivity; however, the erratic penetration of vancomycin into cerebrospinal fluid (especially during concomitant use of dexamethasone) and reports of clinical failures make it less than optimal when used alone to treat pneumococcal meningitis.

Oral vancomycin is used to treat Clostridioides (formerly, Clostridium) difficile–induced diarrhea Clostridioides (formerly Clostridium) difficile–Induced Diarrhea Toxins produced by Clostridioides difficile strains in the gastrointestinal tract cause pseudomembranous colitis, typically after antibiotic use. Symptoms are diarrhea, sometimes bloody, rarely... read more (pseudomembranous colitis). Vancomycin is recommended over metronidazole for an initial episode of nonsevere C. difficile infection. It is preferred over metronidazole for patients who have severe C. difficile infection and is preferred for patients who do not respond to metronidazole.

Contraindications to Vancomycin

Vancomycin is contraindicated in patients who have had an allergic reaction to it.

Use During Pregnancy and Breastfeeding

Animal reproduction studies with vancomycin have not shown risk to the fetus. Evidence in human studies is inadequate. Vancomycin should be given to pregnant women only if clearly needed. Oral vancomycin can be used to treat C. difficile–induced diarrhea in pregnant women.

Vancomycin enters breast milk, and so its use during breastfeeding is discouraged to prevent disruption of gastrointestinal microflora; however, because oral absorption is poor from a normal gastrointestinal tract, systemic adverse effects in infants are unlikely.

Adverse Effects of Vancomycin

The main concern with vancomycin is

  • Hypersensitivity (allergic or due to direct mast-cell degranulation)

Vancomycin should be infused over ≥ 60 minutes to avoid red-person syndrome (a histamine-mediated reaction that can cause pruritus and flushing on the face, neck, and shoulders). Other hypersensitivity reactions (eg, rash, fever) may occur, especially when therapy lasts for > 2 weeks.

Other adverse effects include reversible neutropenia and thrombocytopenia. Nephrotoxicity is rare unless high doses are used or other nephrotoxins (eg, aminoglycosides) are given concomitantly. Some reports suggest that concomitant use of piperacillin/tazobactam may also increase risk of nephrotoxicity. Phlebitis occurs uncommonly during IV infusion.

Dose-related ototoxicity is unusual with current formulations; incidence is increased when vancomycin is given concurrently with other ototoxic drugs.

Dosing Considerations for Vancomycin

Doses used for meningitis must be higher than usual.

Dose reduction is required in renal insufficiency.

In patients with documented or suspected invasive methicillin-resistant S. aureus (MRSA) infection, vancomycin should be dosed to target an area under the concentration-time curve (AUC) of 400 to 600. Targeting troughs as a surrogate marker for achieving an AUC-to-minimum inhibitory concentration (AUC/MIC) ratio of ≥ 400 is no longer recommended. Dose optimization can be done by getting multiple postdistribution levels (1 to 2 hours after the end of the infusion and a trough) and calculating the AUC using first-order kinetic equations, using a software-based Bayesian approach using 1 or 2 levels, or by titrating a continuous infusion to a steady-state concentration of 20 to 25 mcg/mL (13.8 to 17.25 micromol/L). (See also the vancomycin dosing guidelines revised by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.)

These dosing recommendations apply only to MRSA and should not be used to guide dosing for other gram-positive infections.

Vancomycin MICs for many pathogens have been increasing during the past decade. Sensitivity for S. aureus based on vancomycin MIC is as follows:

  • ≤ 2 mcg/mL (≤ 1.4 micromol/L): Sensitive

  • 4 to 8 mcg/mL (2.8 to 5.5 micromol/L): Intermediate

  • > 8 mcg/mL (> 5.5 micromol/L): Resistant

However, infections due to S. aureus with a vancomycin MIC ≥ 2 mcg/mL (≥ 1.4 micromol/L) may respond suboptimally to standard dosing even when the daily AUC is 400 to 600, so the threshold for changing to an alternative therapy should be low for patients with poor clinical response and an MIC of ≥ 2.

More Information

  • Vancomycin dosing guidelines revised by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists

Drugs Mentioned In This Article

Drug Name Select Trade
No US brand name
CLEOCIN
CUBICIN
FLAGYL
MONUROL
ZYVOX
VIBATIV
DALVANCE
SIVEXTRO
ORBACTIV
BACTROBAN
AZACTAM
VANCOCIN
TINDAMAX
FORTAZ, TAZICEF
ZITHROMAX
BIAXIN
ERY-TAB, ERYTHROCIN
DIFICID
No US brand name
No US brand name
GENOPTIC
ANCEF, KEFZOL
FURADANTIN, MACROBID, MACRODANTIN
KEFLEX
THAM
No US brand name
CEFOTAN
MEFOXIN
No US brand name
CEFTIN, ZINACEF
No US brand name
No US brand name
SUPRAX
CLAFORAN
No US brand name
No US brand name
No US brand name
MAXIPIME
No US brand name
BACIIM
TYGACIL
ACHROMYCIN V
MINOCIN
BICILLIN L-A
No US brand name
PRIMSOL
MYCOBUTIN
VIBRAMYCIN
XERAVA
RIFADIN, RIMACTANE
No US brand name
PRIFTIN
XIFAXAN
DORIBAX
INVANZ
MERREM
AMOXIL
SULFAMYLON
No US brand name
BLEPH-10
No US brand name
NALLPEN IN PLASTIC CONTAINER
BACTOCILL IN PLASTIC CONTAINER
AZULFIDINE
BACTRIM, SEPTRA
DARAPRIM
SILVADENE
QUALAQUIN
CILOXAN, CIPRO
No US brand name
ZEMDRI
No US brand name
TOBI, TOBREX
No US brand name
NUZYRA
No US brand name
COLY-MYCIN M
ARALEN
PROGRAF
TIKOSYN
SEROQUEL
LANOXIN
OZURDEX
DILANTIN
LANIAZID
No US brand name
NARDIL
MARPLAN
DEMEROL
WELLBUTRIN, ZYBAN
No US brand name
SYNERCID
PROZAC, SARAFEM
ELIXOPHYLLIN
ANTABUSE
COUMADIN
ACZONE
No US brand name
No US brand name
OCUFLOX
AFRINOL, SUDAFED
ADRENALIN
LEVOPHED
BAXDELA
FACTIVE
LEVAQUIN
AVELOX
No US brand name
No US brand name
ZYMAR
No US brand name
ORAP
ZOSYN
CORTEF, SOLU-CORTEF
No US brand name
No US brand name
Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Professionals also read
Test your knowledge
Trimethoprim and Sulfamethoxazole
Both trimethoprim (TMP) and sulfamethoxazole (SMX) are well absorbed orally, are excreted in the urine, and penetrate well into tissues and body fluids. The combination of these drugs is active against which of the following?
Download the Manuals App iOS ANDROID
Download the Manuals App iOS ANDROID
Download the Manuals App iOS ANDROID
 

Also of Interest

 
TOP